Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplantation Team. 1994

K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
Department of Hematology, Tokyo Metropolitan Komagome Hospital, Japan.

A case of pure red cell aplasia after major ABO-incompatible bone marrow transplantation with long duration of up to 482 days is presented. The patient exhibited resistance to treatment using intravenous gamma globulin, prednisolone and 8 week administration of erythropoietin. The patient finally responded to treatment using erythropoietin and methylprednisolone simultaneously. Because of its safety and efficacy, it might be worthwhile to try erythropoietin with methylprednisolone, if necessary, for pure red cell aplasia complicating major ABO-incompatible bone marrow transplantation.

UI MeSH Term Description Entries
D008297 Male Males
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D012010 Red-Cell Aplasia, Pure Suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Aplasia Pure Red Cell,Erythrocyte Aplasia,Pure Red-Cell Aplasia,Aplasia, Erythrocyte,Aplasia, Pure Red-Cell,Aplasias, Erythrocyte,Erythrocyte Aplasias,Pure Red Cell Aplasia,Pure Red-Cell Aplasias,Red Cell Aplasia, Pure,Red-Cell Aplasias, Pure
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D006648 Histocompatibility The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts. HLA Incompatibility,Histoincompatibility,Human Leukocyte Antigen Incompatibility,Immunocompatibility,Tissue Compatibility,Compatibility, Tissue,HLA Incompatibilities,Histocompatibilities,Histoincompatibilities,Immunocompatibilities,Incompatibility, HLA,Tissue Compatibilities
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
February 1991, Blood,
K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
May 1993, Transfusion,
K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
December 1997, Bone marrow transplantation,
K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
January 1990, Acta haematologica,
K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
January 1996, Transplant international : official journal of the European Society for Organ Transplantation,
K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
January 1990, Blood,
K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
August 2007, American journal of hematology,
K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
November 1992, Bone marrow transplantation,
K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
May 2021, British journal of haematology,
K Ohashi, and H Akiyama, and S Takamoto, and S Tanikawa, and H Sakamaki, and Y Onozawa
September 2005, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Copied contents to your clipboard!